Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 6/20 | 0.35 |
| ▸ | TSHR | P16473 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.32 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295062 | 0.83 | L3MBTL1 (0.33) | L3MBTL1LMNACYP2A6PDE7ATSHR | |
| SCHEMBL23159726 | 0.80 | ADORA2B (0.40) | L3MBTL1LMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL21295088 | 0.80 | L3MBTL1 (0.33) | L3MBTL1LMNACYP2A6TSHRMAPT | |
| SCHEMBL21295057 | 0.78 | TSHR (0.33) | L3MBTL1LMNACYP2A6TSHRMAPT | |
| SCHEMBL21295089 | 0.77 | FEN1 (0.36) | L3MBTL1LMNACYP2A6TSHRTP53 | |
| SCHEMBL26606790 | 0.74 | L3MBTL1 (0.35) | L3MBTL1LMNACYP2A6PDE7ATSHR | |
| SCHEMBL21295034 | 0.73 | CYP2A6 (0.33) | LMNACYP2A6PDE7AALDH1A1 | |
| SCHEMBL2330722 | 0.72 | GPR35 (0.50) | L3MBTL1LMNATSHRMAPTSMN1; SMN2 | |
| SCHEMBL21307282 | 0.71 | TSHR (0.37) | L3MBTL1LMNAPDE7ATSHRMAPT | |
| SCHEMBL21307349 | 0.70 | ALDH1A1 (0.30) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110194770-B | Peptidyl arginine deiminase inhibitors and uses thereof | 药捷安康(南京)科技股份有限公司 | 2022-08-09 | — | — | CN | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| EP-3760628-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | Nanjing Transthera Biosciences Co., Ltd. (CN) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | NANJING TRANSTHERA BIOSCIENCES CO., LTD. (CN) | 2020-12-31 | — | — | US | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
| WO-2019161803-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | 南京药捷安康生物科技有限公司 | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200407370-A1 | PEPTIDYLARGININE DEIMINASE INHIBITOR AND USE THEREOF | PADI4, PADI2, PADI1 | L3MBTL1 2762/4885LMNA 3737/4885CYP2A6 3724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.